Allergy Immunotherapy Market (Treatment Type - Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT); Allergy Type - Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy; Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Description

Allergy Immunotherapy Market – Snapshot

The global allergy immunotherapy market is expanding at a considerable pace due to high prevalence and rise in incidences of allergies across the globe. The global allergy immunotherapy market was valued at US$ 1.37 Bn in 2016 and is projected to expand at CAGR of 10.7% from 2017 to 2025 to exceed the US$ 3.33 Bn by 2025. Expansion of the global allergy immunotherapy market is attributed to the rise in awareness regarding allergy treatment, rapidly growing allergic population, and launch of new products.

Allergy immunotherapy, also referred to as desensitization or hypo-sensitization, is a medical treatment targeted for different types of allergies. There is an increase in prevalence of allergy and pharmacotherapy alone is insufficient to control the disease. The allergy immunotherapeutic treatment helps increase immunological tolerance and alters the disease course. The desensitization therapy provides long-term effect, which extends past the conclusion of treatment. This therapy helps improve the quality of life of patients with allergies.

As per the World Allergy Organization (WAO), there has been a significant rise in prevalence of allergic diseases across the world in last 50 years. According to Summary Health Statistics for U.S. Adults: 2010 National Health Interview Survey, over 8% and 13% of adult people in the U.S. have hay fever and sinusitis, respectively. According to WAO, around 30% of the global population suffers from allergic rhinitis alone. Thereby, high prevalence and incidence rate of allergy across the globe are driving the global allergy immunotherapy market. Additionally, increase in awareness about allergy treatment and high clinical R&D budget by governments and non-profit organizations are projected to fuel the allergy immunotherapy market during the forecast period. Promising product pipeline creates opportunities for business development during the forecast period. Across the world, there are around 10 different drugs in phase-3 of the clinical pipeline studies for treating different allergy symptoms.

The subcutaneous immunotherapy (SCIT), is extensively used and effective form of allergy immunotherapy. The SCIT treatment alters the immune system, thereby preventing the development of new allergies and asthma. Allergy tablets are a type of SLIT that treat certain allergies. These allergy tablets decrease the symptoms by helping the body build resistance to allergen effects. However, tablets can only treat a single type of allergen and do not avoid new allergies development and asthma. In 2014, the US Food and Drug administration (FDA) approved SLIT tablets to treat ragweed and grass pollen allergies.

The global allergy immunotherapy market is divided into four segments based on treatment type, allergy type, distribution channel, and geography. In terms of treatment type, the global allergy immunotherapy market is segmented into SCIT and SLIT. SCIT dominated the global allergy immunotherapy market in 2016, account for more than 65% share of the market. The segment is projected to expand at a moderate pace and gain market share during the forecast period.

In terms of allergy type, the global allergy immunotherapy market is classified into allergic rhinitis, asthma, food allergy, venom allergy, and others. The allergic rhinitis segment accounted for a leading share of the global market. The segment is projected to continue its dominance during the forecast period. The asthma segment accounted for a significant share of the market due to effectiveness of SCIT and SLIT in the treatment of allergic asthma. The other segment includes allergies such as latex allergy, pollen allergy, and mold allergy. Distribution channels include hospital pharmacies, retail pharmacies & drug stories, and online pharmacies. The hospital pharmacies segment dominated the global allergy immunotherapy market in 2016 and is likely to gain share by the end of 2025.

Geographically, the allergy immunotherapy market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for the largest share of the global allergy immunotherapy market in 2016, followed by North America. Europe accounts for a large share of the market due to high awareness, increase in funding for research and grants, favorable medical reimbursement policies, rise in allergic population, and promising clinical pipeline products. The region is a highly attractive market and is anticipated to expand at a significant CAGR during the forecast period. The allergy immunotherapy market in Asia Pacific is anticipated to expand at a moderate growth rate. Majority of the market share of allergy immunotherapy is captured by Japan and China in Asia-Pacific region, owing to the presence of huge allergic population in these countries.

The global allergy immunotherapy market is consolidated with some companies accounting for majority share. Leading players operating in the global allergy immunotherapy market include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Merck KGaA (Allergopharma),  and HAL Allergy Group. Manufacturers are adopting new SLIT therapies commercialization in the international market to tap the unmet needs of allergy immunotherapy. Other prominent players operating in the global market include Biomay AG, Anergis, Aimmune Therapeutics, Circassia and DBV Technologies.

The global allergy immunotherapy market has been segmented as follows:

Treatment Type

  • SCIT (Subcutaneous Immunotherapy)
  • SLIT (Sublingual Immunotherapy)

Allergy Type

  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy and Drug Stores
  • Online Pharmacy

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Allergy Immunotherapy Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Allergy Immunotherapy Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Allergy Immunotherapy Market Outlook

Chapter 6 Global Allergy Immunotherapy Market Analysis and Forecast, by Treatment Type
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       6.3.1. Subcutaneous Immunotherapy (SCIT)
       6.3.2. Sublingual Immunotherapy(SLIT)
6.4. Market Attractiveness Analysis, by Treatment Type

Chapter 7 Global Allergy Immunotherapy Market Analysis and Forecast, by Allergy Type
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Allergy Type, 2017–2025
       7.2.1. Allergic Rhinitis
       7.2.2. Asthma
       7.2.3. Food Allergy
       7.2.4. Venom Allergy
       7.2.5. Others
7.3. Market Attractiveness Analysis, by Allergy Type
7.4. Key Trends

Chapter 8 Global Allergy Immunotherapy Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017–2025
       8.3.1. Hospital Pharmacy
       8.3.2. Retail Pharmacy and Drug Stores
       8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Allergy Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017–2025
       9.3.1. North America
       9.3.2. Europe
       9.3.3. Asia Pacific
       9.3.4. Latin America
       9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Allergy Immunotherapy Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
       10.2.1. U.S.
       10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       10.3.1. SCIT
       10.3.2. SLIT
10.4. Market Size (US$ Mn) Forecast, by Allergy Type, 2017–2025
       10.4.1. Allergic Rhinitis
       10.4.2. Asthma
       10.4.3. Food Allergy
       10.4.4. Venom Allergy
       10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017–2025
       10.5.1. Hospital Pharmacy
       10.5.2. Retail Pharmacy and Drug Stores
       10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
       10.6.1. By Country
       10.6.2. By Treatment Type
       10.6.3. By Allergy Type
       10.6.4. By Distribution Channel

Chapter 11 Europe Allergy Immunotherapy Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
       11.2.1. Germany
       11.2.2. U.K.
       11.2.3. France
       11.2.4. Italy
       11.2.5. Spain
       11.2.6. Russia
       11.2.7. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       11.3.1. SCIT
       11.3.2. SLIT
11.4. Market Size (US$ Mn) Forecast, by Allergy Type, 2017–2025
       11.4.1. Allergic Rhinitis
       11.4.2. Asthma
       11.4.3. Food Allergy
       11.4.4. Venom Allergy
       11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
       11.5.1. Hospital Pharmacy
       11.5.2. Retail Pharmacy and Drug Stores
       11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
       11.6.1. By Country
       11.6.2. By Treatment Type
       11.6.3. By Allergy Type
       11.6.4. By Distribution Channel

Chapter 12 Asia Pacific Allergy Immunotherapy Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
       12.3.1. China
       12.3.2. India
       12.3.3. Japan
       12.3.4. Australia & New Zealand
       12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       12.4.1. SCIT
       12.4.2. SLIT
12.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017–2025
       12.5.1. Allergic Rhinitis
       12.5.2. Asthma
       12.5.3. Food Allergy
       12.5.4. Venom Allergy
       12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017–2025
       12.6.1. Hospital Pharmacy
       12.6.2. Retail Pharmacy and Drug Stores
       12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
       12.7.1. By Country
       12.7.2. By Treatment Type
       12.7.3. By Allergy Type
       12.7.4. By Distribution Channel

Chapter 13 Latin America Allergy Immunotherapy Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
       13.3.1. Brazil
       13.3.2. Mexico
       13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       13.4.1. SCIT
       13.4.2. SLIT
13.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
       13.5.1. Allergic Rhinitis
       13.5.2. Asthma
       13.5.3. Food Allergy
       13.5.4. Venom Allergy
       13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017–2025
       13.6.1. Hospital Pharmacy
       13.6.2. Retail Pharmacy and Drug Stores
       13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
       13.7.1. By Country/Sub-region
       13.7.2. By Treatment Type
       13.7.3. By Allergy Type
       13.7.4. By Distribution Channel

Chapter 14 Middle East & Africa Allergy Immunotherapy Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
       14.3.1. GCC Countries
       14.3.2. South Africa
       14.3.3. Israel
       14.3.4. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2025
       14.4.1. SCIT
       14.4.2. SLIT
14.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017–2025
       14.5.1. Allergic Rhinitis
       14.5.2. Asthma
       14.5.3. Food Allergy
       14.5.4. Venom Allergy
       14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
       14.6.1. Hospital Pharmacy
       14.6.2. Retail Pharmacy and Drug Stores
       14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
       14.7.1. By Country/Sub-region
       14.7.2. By Treatment Type
       14.7.3. By Allergy Type
       14.7.4. By Distribution Channel

Chapter 15 Pipeline Analysis
       15.1.1. Allergy Immunotherapy Pipeline Analysis (2017)

Chapter 16 Allergy Immunotherapy – Regulatory Overview
       16.1.1. Regulatory Status for European Union
       16.1.2. Regulatory Status for U.S.

Chapter 17 Competition Landscape
17.1. Global Allergy Immunotherapy Market Share, by Company, 2017
17.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
       17.2.1. ALK-Abello A/S
                 17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.1.2. Product Portfolio
                 17.2.1.3. SWOT Analysis
                 17.2.1.4. Strategic Overview
       17.2.2. Allergy Therapeutics
                 17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.2.2. Product Portfolio
                 17.2.2.3. SWOT Analysis
                 17.2.2.4. Strategic Overview
       17.2.3. Stallergenes Greer
                 17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.3.2. Product Portfolio
                 17.2.3.3. SWOT Analysis
                 17.2.3.4. Financial Overview
                 17.2.3.5. Strategic Overview
       17.2.4. HAL Allergy Group
                 17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.4.2. Product Portfolio
                 17.2.4.3. SWOT Analysis
                 17.2.4.4. Financial Overview
                 17.2.4.5. Strategic Overview
       17.2.5. DBV Technologies
                 17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.5.2. Product Portfolio
                 17.2.5.3. SWOT Analysis
                 17.2.5.4. Financial Overview
                 17.2.5.5. Strategic Overview
       17.2.6. Merck KGaA
                 17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.6.2. Product Portfolio
                 17.2.6.3. SWOT Analysis
                 17.2.6.4. Financial Overview
                 17.2.6.5. Strategic Overview
       17.2.7. Aimmune Therapeutics
                 17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.7.2. Product Portfolio
                 17.2.7.3. SWOT Analysis
                 17.2.7.4. Financial Overview
                 17.2.7.5. Strategic Overview
       17.2.8. Circassia
                 17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.8.2. Product Portfolio
                 17.2.8.3. SWOT Analysis
                 17.2.8.4. Financial Overview
                 17.2.8.5. Strategic Overview
       17.2.9. Anergis
                 17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.9.2. Product Portfolio
                 17.2.9.3. SWOT Analysis
                 17.2.9.4. Financial Overview
                 17.2.9.5. Strategic Overview
       17.2.10. Biomay AG
                 17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                 17.2.10.2. Product Portfolio
                 17.2.10.3. SWOT Analysis
                 17.2.10.4. Financial Overview
                 17.2.10.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample